PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
A prospective, open-abel, phase 2 clinical study to investigate whether interim Positron
Emission Tomography (PET) and Epstein-Barr virus (EBV) DNA-directed therapy can improve the
prognosis of localized nasal extranodal NK/T cell lymphoma (ENKTL) patients.